Effects of oxidative stress on the pharmacokinetics and hepatic metabolism of atazanavir in rats

References

• Bevilacqua M, Dominguez LJ, Barbagallo M. Insulin Resistance and the cardiometabolic syndrome in HIV infection. J Cardiometab Syndr 2009;4:40–43.
   PubMedGoogle Scholar
• Ivanovic J, Nicastri E, Ascenzi P, Bellagamba R, De Marinis E, Notari S, . Therapeutic drug monitoring in the management of HIV-infected patients. Curr Med Chem 2008;15:1925–1939.
   PubMedGoogle Scholar
• Colonno R, Rose R, McLaren C, Thiry A, Parkin N, Friborg J. Identification of I50L as the signature atazanavir (ATV)- resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J Infect Dis 2004;189: 1802–1810.
   PubMed Web of Science ®Google Scholar
• Wood R, Phanuphak P, Cahn P, Pokrovskiy V, Rozenbaum W, Pantaleo G, . Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr 2004;36:684–692.
   PubMed Web of Science ®Google Scholar
• Atazanavir (REYATAZ®) [Drug Information]. Bristol-Myers Squibb Company. 2011.
   Google Scholar
• Drug Bank database [Internet], available at the University of Alberta, Alberta, Canada. [Drug created on June 13, 2005/Updated on February 14, 2012]. Available from: http://www.drugbank.ca/drugs/DB01072.
   Google Scholar
• Wasan KM, Brocks DR, Lee SD, Sachs-Barrable K, Thornton SJ. Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery. Nat Rev Drug Discov 2008;7:84–99.
   PubMed Web of Science ®Google Scholar
• Fukushima K, Shibata M, Mizuhara K, Aoyama H, Uchisako R, Kobuchi S, . Effect of serum lipids on the pharmacokinetics of atazanavir in hyperlipidemic rats. Biomed Pharmacother 2009;63:635–642.
   PubMed Web of Science ®Google Scholar
• Oguntibeju OO. Quality of life of people living with HIV and AIDS and antiretroviral therapy. HIV/AIDS 2012;4:117–124.
   Google Scholar
• Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Life Sci 2009;84:705–712.
   PubMed Web of Science ®Google Scholar
• Ngondi JL, Oben J, Forkah DM, Etame LU, Mbanya D. The effect of different combination therapies on oxidative stress markers in HIV-infected patients in Cameroon. AIDS Res Ther 2006;3:19.
   PubMedGoogle Scholar
• Mates JM, Segura JA, Alonso FJ, Marquez J. Intracellular redox status and oxidative stress: implications for cell proliferation, apoptosis, and carcinogenesis. Arch Toxicol 2008;82: 273–299.
   PubMed Web of Science ®Google Scholar
• Deiana M, Rosa A, Corona G, Collu S, Ennas MG, Dessi MA. Lipid peroxidation in plasma of rats treated with ferric-nitrilotriacetate, in relation to kidney and liver modifications. Biofactors 2005;23:35–44.
   PubMedGoogle Scholar
• Iqbal M, Giri U, Athar M. Ferric nitrilotriacetate (Fe-NTA) is a potent hepatic tumor promoter and acts through the generation of oxidative stress. Biochem Biophys Res Commun 1995;212:557–563.
   PubMed Web of Science ®Google Scholar
• Athar M, Iqbal M. Ferric nitrilotriacetate promotes N-diethylnitrosamine-induced renal tumorigenesis in the rat: implications for the involvement of oxidative stress. Carcinogenesis 1998;19:1133–1139.
   PubMed Web of Science ®Google Scholar
• Kuroda Y, Cao B, Shibukawa A, Nakagawa T. Effect of oxidation of low-density lipoprotein on drug binding affinity studied by high performance frontal analysis-capillary electrophoresis. Electrophoresis 2001;22:3401–3407.
   PubMedGoogle Scholar
• Matsushita R, Kondo Y, Yada S, Miyamoto K. Proceedings of the 18th meeting of Japanese Society of Pharmaceutical Health Care and Sciences. Japanese Society of Pharmaceutical Health Care and Sciences; 2008 September 20–21; Sapporo. Japan: Japanese Society of Pharmaceutical Health Care and Sciences; 2008. 358 p.
   Google Scholar
• Kondo Y, Matsushita R, Yada S, Miyamoto K. Proceedings of the 25th Japanese Society of Therapeutic Drug Monitoring; 2008 June 21–22; Kobe. Japan: The Japanese Society of Therapeutic Drug Monitoring; 2008. 167 p.
   Google Scholar
• Kobuchi S, Fukushima K, Aoyama H, Matsuda T, Ito Y, Sugioka N, Takada K. Effect of oxidative stress on the pharmacokinetics of clomipramine in rats treated with ferric- nitrilotriacetate. Drug Metab Lett 2011;5:243–252.
   PubMedGoogle Scholar
• Kobuchi S, Fukushima K, Ito Y, Sugioka N, Takada K. Pharmacokinetics and distribution of fluvoxamine to the brain in rats under oxidative stress. Free Radic Res 2012;46: 831–841.
   PubMed Web of Science ®Google Scholar
• Awai M, Narasaki M, Yamanoi Y, Seno S. Induction of diabetes in animals by parenteral administration of ferric nitrilotriacetate. A model of experimental hemochromatosis. Am J Pathol 1979;95:663–673.
   PubMed Web of Science ®Google Scholar
• Buege JA, Aust SD. Microsomal lipid peroxidation. Meth Enzymol 1978;52:302–310.
   PubMedGoogle Scholar
• Hayes KA, Brennan B, Chenery R, Houston JB. In vivo disposition of caffeine predicted from hepatic microsomal and hepatocyte data. Drug Metab Dispos Biol Fate Chem 1995;23:349–353.
   PubMed Web of Science ®Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265–275.
   PubMed Web of Science ®Google Scholar
• Kurokawa S, Niwano S, Niwano H, Ishikawa S, Kishihara J, Aoyama Y, . Progression of ventricular remodeling and arrhythmia in the primary hyperoxidative state of glutathione-depleted rats. Circ J 2011;75:1386–1393.
   PubMedGoogle Scholar
• Schuhmacher J, Buhner K, Witt-Laido A. Determination of the free fraction and relative free fraction of drugs strongly bound to plasma proteins. J Pharm Sci 2000;89:1008–1021.
   PubMed Web of Science ®Google Scholar
• Monks A, Richens A. Plasma protein binding interaction between valproic acid and palmitic acid in vitro [proceedings]. Br J Clin Pharmacol 1978;6:448.
   Google Scholar
• Sugioka N, Sato K, Haraya K, Maeda Y, Yasuda K, Fukushima K, . Effect of streptozotocin-induced diabetes mellitus on the pharmacokinetics of nelfinavir in rats. Biopharm Drug Dispos 2008;29:469–479.
   PubMed Web of Science ®Google Scholar
• Gao W, Kishida T, Kimura K, Kageyama M, Sumi M, Yoshikawa Y, . Sensitive and simultaneous determination of HIV protease inhibitors in rat biological samples by liquid chromatography-mass spectrometry. Biomed Chromatogr 2002;16:267–273.
   PubMed Web of Science ®Google Scholar
• Matos HR, Capelozzi VL, Gomes OF, Mascio PD, Medeiros MH. Lycopene inhibits DNA damage and liver necrosis in rats treated with ferric nitrilotriacetate. Arch Biochem Biophys 2001;396:171–177.
   PubMed Web of Science ®Google Scholar
• Carini R, Parola M, Dianzani MU, Albano E. Mitochondrial damage and its role in causing hepatocyte injury during stimulation of lipid peroxidation by iron nitriloacetate. Arch Biochem Biophys 1992;297:110–118.
   PubMedGoogle Scholar
• Hamazaki S, Okada S, Li JL, Toyokuni S, Midorikawa O. Oxygen reduction and lipid peroxidation by iron chelates with special reference to ferric nitrilotriacetate. Arch Biochem Biophys 1989;272:10–17.
   PubMed Web of Science ®Google Scholar
• Ueno S, Kashimoto T, Susa N, Shiho K, Seki T, Ito N, . Estimation of hydroxyl radical generation by salicylate hydroxylation method in kidney of mice exposed to ferric nitrilotriacetate and potassium bromate. Free Radic Res 2007;41:1246–1252.
   PubMed Web of Science ®Google Scholar
• Toyokuni S. Iron-induced carcinogenesis: the role of redox regulation. Free Radic Biol Med 1996;20:553–566.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Sun F, Tanaka K, Tokumaru S, Kojo S. Increase of lipid hydroperoxides in the rat liver and kidney after administering ferric nitrilotriacetate. Biosci Biotechnol Biochem 1998;62:1438–1439.
   PubMed Web of Science ®Google Scholar
• Rosa A, Deiana M, Corona G, Atzeri A, Incani A, Appendino G, Dessì MA. Protective effect of capsinoid on lipid peroxidation in rat tissues induced by Fe-NTA. Free Radic Res 2005;39:1155–1162.
   PubMed Web of Science ®Google Scholar
• Gershkovich P, Hoffman A. Uptake of lipophilic drugs by plasma derived isolated chylomicrons: linear correlation with intestinal lymphatic bioavailability. Eur J Pharm Sci 2005;26:394–404.
   PubMed Web of Science ®Google Scholar
• Parthasarathy S, Raghavamenon A, Garelnabi MO, Santanam N. Oxidized low-density lipoprotein. Methods Mol Biol 2010; 610:403–417.
   PubMedGoogle Scholar
• Suzuki Y, Ohkubo N, Aoto M, Maeda N, Cicha I, Miki T, Mitsuda N. Participation of caspase-3-like protease in oxidation-induced impairment of erythrocyte membrane properties. Biorheology 2007;44:179–190.
   PubMedGoogle Scholar
• Bates GW, Schlabach MR. The reaction of ferric salts with transferrin. J Biol Chem 1973;248:3228–3232.
   PubMed Web of Science ®Google Scholar
• Ikuta K, Torimoto Y, Kohgo Y. Iron metabolism of the liver. Clinical Gastroenterology. Tokyo, Japan: Nihon Medical Center, Inc.; 2008;23:701–708.
   Google Scholar
• Perloff ES, Duan SX, Skolnik PR, Greenblatt DJ, von Moltke LL. Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos 2005;33: 764–770.
   PubMed Web of Science ®Google Scholar
• Hogberg J, Bergstrand A, Jakobsson SV. Lipid peroxidation of rat-liver microsomes. Its effect on the microsomal membrane and some membrane-bound microsomal enzymes. Eur J Biochem 1973;37:51–59.
   PubMedGoogle Scholar
• Cederbaum AI. Iron and CYP2E1-dependent oxidative stress and toxicity. Alcohol 2003;30:115–120.
   PubMedGoogle Scholar
• Smedsrod B, Melkko J, Araki N, Sano H, Horiuchi S. Advanced glycation end products are eliminated by scavenger-receptor-mediated endocytosis in hepatic sinusoidal Kupffer and endothelial cells. Biochem J 1997;322:567–573.
   PubMed Web of Science ®Google Scholar
• Nagelkerke JF, Barto KP, van Berkel TJ. In vivo and in vitro uptake and degradation of acetylated low density lipoprotein by rat liver endothelial, Kupffer, and parenchymal cells. J Biol Chem 1983;258:12221–12227.
   PubMed Web of Science ®Google Scholar
• Tomita M, Takizawa Y, Kishimoto H, Hayashi M. Effect of intestinal ischaemia/reperfusion on P-glycoprotein-mediated ileal excretion of rhodamine 123 in the rat. J Pharm Pharmacol 2009;61:1319–1324.
   PubMed Web of Science ®Google Scholar
• Sugioka N, Takai M, Yoshida K, Yasuda K, Fukushima K, Kokuhu T, . Effect of plasma uric acid on pharmacokinetics of cyclosporine A in living-related renal transplant recipients and pharmacokinetic study in rats with experimental hyperuricaemia. J Clin Pharm Ther 2010;35: 323–332.
   PubMedGoogle Scholar